Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4967
Source ID: NCT04287179
Associated Drug: Semaglutide
Title: SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
Acronym: SUSTAIN SWITCH
Status: WITHDRAWN
Study Results: NO
Results:
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG: Semaglutide
Outcome Measures: Primary: Change in glycosylated haemoglobin (HbA1c), Percent-point, From baseline (week 0) to week 12 | Secondary: Change in fasting plasma glucose, mmol/L, From baseline (week 0) to week 12|Change in body weight, Kg, From baseline (week 0) to week 12|Number of treatment emergent adverse events (TEAEs), Count, From baseline (week 0) to week 12|Number of treatment emergent gastrointestinal adverse events, Count, From baseline (week 0) to week 12|Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes, Count, From baseline (week 0) to week 12|Change in pulse rate, Beats per minute (bpm), From baseline (week 0) to week 12|Number of treatment emergent adverse events (TEAEs), Count, From week 12 to week 17
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 0
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2020-03-09
Completion Date: 2021-01-25
Results First Posted:
Last Update Posted: 2022-02-03
Locations: Novo Nordisk Investigational Site, Buena Park, California, 90620, United States|Novo Nordisk Investigational Site, Fresno, California, 93720, United States|Novo Nordisk Investigational Site, San Jose, California, 95148, United States|Novo Nordisk Investigational Site, Walnut Creek, California, 94598, United States|Novo Nordisk Investigational Site, Waterbury, Connecticut, 06708, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, 96814, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, 83404-7596, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, 46260, United States|Novo Nordisk Investigational Site, Troy, Michigan, 48098, United States|Novo Nordisk Investigational Site, Albany, New York, 12206, United States|Novo Nordisk Investigational Site, West Seneca, New York, 14224, United States|Novo Nordisk Investigational Site, Dallas, Texas, 75390-9302, United States|Novo Nordisk Investigational Site, Round Rock, Texas, 78681, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, 77478, United States|Novo Nordisk Investigational Site, Graz, 8036, Austria|Novo Nordisk Investigational Site, Stockerau, 2000, Austria|Novo Nordisk Investigational Site, Wien, 1090, Austria|Novo Nordisk Investigational Site, Wien, 1130, Austria|Novo Nordisk Investigational Site, Jyväskylä, 40100, Finland|Novo Nordisk Investigational Site, Kuopio, 70100, Finland|Novo Nordisk Investigational Site, Lahti, 15100, Finland|Novo Nordisk Investigational Site, Raisio, 21200, Finland|Novo Nordisk Investigational Site, Seinäjoki, 60220, Finland|Novo Nordisk Investigational Site, Göteborg, 413 45, Sweden|Novo Nordisk Investigational Site, Malmö, 205 02, Sweden
URL: https://clinicaltrials.gov/show/NCT04287179

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress